Sign Up to like & get
recommendations!
0
Published in 2017 at "Microbial Cell Factories"
DOI: 10.1186/s12934-017-0801-y
Abstract: Staphylokinase (Sak) holds promise for use in thrombolytic therapy for acute myocardial infarction. However, its immunogenicity is a major disadvantage under clinical conditions. PEGylation has become a sophisticated method to decrease that immunogenicity. In this…
read more here.
Keywords:
sak;
peg sak;
sak c104r;
pegylation ... See more keywords